AI in Medicine — Cancer & Rare Disease — 2026-09-27 (Sun)

Latest news on AI and cancer treatment

Overview

There was movement in obtaining approvals and permits for the diagnostic/pathology field (radiology, pathology, endoscopic AI) and cancer testing labs. In the area of drug discovery and treatment selection, articles mainly introduce cloud computing platforms and technology trends. There are no new regulatory approvals (FDA/EMA/PMDA).

Breast cancer

It was reported that Ataraxis AI's testing laboratory has obtained CAP (College of American Pathologists) certification and California Clinical Laboratory License. Target cancer types and specific clinical performance values are not listed in the heading.

lung cancer

No applicable information

Malignant brain tumor

No applicable information

Leukemia/lymphoma

No applicable information

Colon cancer/digestive organ

The development of an AI model to predict the risk of pancreatic cancer was reported (originated in Iran). The development stage, verification method (preclinical/retrospective research, etc.) and specific prediction accuracy are not listed in the headline.

Rare cancer

No applicable information

Diagnosis/Pathology/Image

- From UCLA: An effort to verify the use of AI in the diagnosis of Alzheimer's disease and dementia was reported (although it is outside the cancer field, it was mentioned as an example of the verification of image diagnosis AI). - AIIMS Director Mangalagiri stated at the India AP IRIA conference that AI should be in a position to complement radiologists (see Section 13 for details). - A ``groundbreaking pilot study'' in which an AI chatbot plans the needle route for liver biopsy was reported. Target diseases, number of cases, and accuracy indicators are not listed in the heading. Only the point that it is a single facility pilot is made clear.

Treatment selection/drug discovery

- An expert in Madison (Wisconsin) said that AI can detect signs of cancer that humans cannot see, but there are limits (see section 13 for details). - Reports that ``AdaptiveFlow,'' a cloud computing platform that utilizes AI, will redefine large-scale drug discovery calculations. Target disease and development stage (preclinical, etc.) are not listed in the heading. - A review article introducing technological trends that are reshaping drug discovery, from molecular glue technology to AI. No description of individual drugs or stages.

Regulations/Approval

No applicable information (Announcements of approvals, designations, and guidelines by the FDA, EMA, and PMDA are not included in the heading. Ataraxis' CAP certification and state testing laboratory license are not covered in this section, as they are different from pharmaceutical approvals by regulatory authorities, and are described in Section 2)

Clinical trial implementation status

The relevant trial name, target cancer type, phase, and registration status were not provided from ClinicalTrials.gov. No applicable information

Japanese movements

The Japan-related headlines collected this time are articles about an AI-based Bon dance (Maruoka Ondo) practice by elementary school students in Sakai City and an AI short film, both of which have nothing to do with cancer medicine or AI. There is no relevant information regarding the use of AI in cancer treatment in Japan.

Remarks from VIPs

- Director of AIIMS Mangalagiri (India): At the AP State IRIA conference, he said that AI should complement radiologists rather than replace them. - Madison area expert (covered by The Cap Times): While AI has the potential to detect signs of cancer that the human eye can't detect, he says it also has limitations. The specific cancer type, detection accuracy, and research stage are not listed in the headline.

*Note: This report has been created within the scope of the information in the headings, and does not include effects, safety, indications, or numerical values not listed in the headings. *